MannKind Corporation Reports Third Quarter 2026 Financial Results
MannKind Corporation announced its financial results for the third quarter of 2026, highlighting the commercial progress of Furoscix ReadyFlow and Afrezza.
Stocks · News reference
Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across injection sites support
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MannKind Corporation to Report Third Quarter 2026 Financial Results on November 5, 2026
MannKind Corporation announced it will release its third quarter 2026 financial results after market close on November 5, 2026, followed by a conference call.
Cantor Fitzgerald Maintains $8.00 Price Target on MannKind
Cantor Fitzgerald has reaffirmed its $8.00 per share price target for MannKind Corporation.
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10
Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.